

Amendments to the Specification

Please replace paragraph [0065] with the following amended paragraph:

The term a "condition that modulates integrins or integrin receptors" refers to any condition that might accomplish integrin or integrin receptor modulation. In addition to the compounds referred to in the earlier ~~previous~~ paragraph, additional examples of modulatory compounds ~~that may be used with modulatory compounds~~ include amyloid beta peptide ~~and mimetics thereof~~, oxidative free radicals (OH, O₂, etc), lysosomal enzyme inhibitors (chloroquine, N-CBZ-L-phenylalanyl-L-alanine-diazomethylketone, NCBZ-L-phenylalanyl-L-phenyl-alanine-diazomethylketon, β-amyloid, and mimetics thereof, etc.), or inflammatory factors (TGFβ, IL-1β, LPS, *etc.*). These compounds can be used individually or in a cocktail containing a combination of more than one compound or in combination with the above ~~modulatory~~ compounds.